MedTrace Logo

EMI-137 in Laparoscopic Colonic Resections

NCT03360461 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2024-05-08

No results posted yet for this study

Summary

EMI-137 in laparoscopic colonic resections is a single-centre stage IIa developmental study.

Ten adult participants with a diagnosis of colon adenocarcinoma undergoing laparoscopic colonic will be recruited to the trial. Participants will receive a single intravenous dose of the IMP - EMI-137 1 to 3 hours before surgery. The ability of EMI-137 to produce visible intra-operative fluorescence of primary colon cancer and lymph node metastases will be explored and evaluated.

Conditions

  • Colonic Cancer
  • Metastasis to Lymph Node

Interventions

DRUG

EMI-137

EMI-137 - a fluorescent c-Met receptor targeted peptide

Sponsors & Collaborators

  • Edinburgh Molecular Imaging Ltd

    collaborator UNKNOWN

  • University of Leeds

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-14
Primary Completion
2020-02-14
Completion
2020-03-14

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03360461 on ClinicalTrials.gov